[ad_1]
JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday.
[ad_2]
Source link
JPMorgan Chase & Co. Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00
